Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

ENLV Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Enlivex Therapeutics Ltd.NASDAQ: ENLV

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development declines year over year

Q4 FY2025 research & development of $3.03M fell 11.4% year over year, ahead of the -13.4% change in trailing-twelve-month research & development. Sequentially, it rose 104.1% from the prior quarter. Over 3 fiscal years it compounded at -21.9% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -11.4% holds above the trailing-twelve-month pace of -13.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$3.03M+104.1% QoQ
Last fiscal yearDec 2025
$8.92M-11.9% YoY
LTMDec 2025
$9.2M-13.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year-11.9%——
3-year CAGR-21.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
8.92M USD
Year-over-year change
-11.9%
4-year CAGR
-8.8%

Research & Development vs competitors

How ENLV compares with its peers on the latest reported figures

  • ENLV's LTM Dec 2025 research & development of $9.2M is the highest of the 2 companies compared; the peer median is $532.62K.
  • Its year-over-year change of -13.4% is the lowest of 2, against a peer median of +104.0%.
  • Over three fiscal years its annual growth of -21.9% compares with a peer median of +29.8%.
ENLV Competitors Peer median
Research & Development for ENLV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$9.2M -13.4%-21.9%—
NRXSNeurAxis, Inc.LTM Mar 2026$532.62K +104.0%+29.8%12.4%
Peer median (excluding ENLV) $532.62K+104.0%+29.8%12.4%

Competitors are the stored peer set for ENLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue546K777K835K545K332K
Gross Profit(546K)(777K)(835K)(545K)(332K)
Gross Margin—————
Research & Development12.88M18.69M19.24M10.13M8.92M
Selling, General & Admin6.24M6.7M6.14M4.91M5.69M
Operating Expenses19.29M25.8M29.4M14.99M14.67M
Depreciation & Amortization546K777K835K545K332K
EBITDA(18.74M)(25.02M)(28.22M)(14.47M)(14.67M)
EBITDA Margin—————
Operating Income(19.29M)(25.8M)(29.4M)(15.54M)(15M)
Operating Margin—————
Interest Income120K835K1.57M1.07M792K
Interest Expense328K5.26M14K13K13K
Other Income / Expenses4.82M(5.26M)327K522K1.63B
Income Before Tax(14.47M)(31.06M)(29.07M)(15.01M)1.62B
Pre-Tax Margin—————
Income Tax Expense0000382.65M
Net Income(14.47M)(31.06M)(29.07M)(15.01M)1.24B
Net Margin—————
EPS (Basic)(8.10)(34.65)(23.40)(10.95)405.60
EPS (Diluted)(8.10)(34.65)(23.40)(10.95)382.20
Weighted Avg Shares1.19M1.23M1.24M1.37M3.05M
Weighted Avg Shares (Diluted)1.19M1.23M1.24M1.37M3.23M

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Intrinsic Alpha fair value

Locked

Current Price

$4.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.